Compare · ARGX vs OTLK
ARGX vs OTLK
Side-by-side comparison of argenx SE (ARGX) and Outlook Therapeutics Inc. (OTLK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and OTLK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 406.1x OTLK ($155.8M).
- Over the past year, ARGX is up 44.0% and OTLK is down 76.2% - ARGX leads by 120.1 points.
- OTLK has been more active in the news (15 items in the past 4 weeks vs 11 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 20 for OTLK).
- Company
- argenx SE
- Outlook Therapeutics Inc.
- Price
- $1019.71+0.82%
- $0.64+6.42%
- Market cap
- $63.27B
- $155.8M
- 1M return
- +14.62%
- -39.62%
- 1Y return
- +43.97%
- -76.18%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2016
- News (4w)
- 11
- 15
- Recent ratings
- 25
- 20
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Outlook Therapeutics Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest OTLK
- SEC Form SCHEDULE 13G filed by Outlook Therapeutics Inc.
- SEC Form 10-Q filed by Outlook Therapeutics Inc.
- SEC Form NT 10-Q filed by Outlook Therapeutics Inc.
- Chief Executive Officer Jahr Robert Charles bought 151,515 shares (SEC Form 4)
- Director Sukhtian Ghiath M. bought $2,499,999 worth of shares (2,525,252 units at $0.99) (SEC Form 4)
- Chief Financial Officer Kenyon Lawrence A bought 101,010 shares, increasing direct ownership by 1,699% to 106,956 units (SEC Form 4)
- Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Outlook Therapeutics Inc.
- Outlook Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™